News & Press
The EIB and GeNeuro sign a EUR 25 million credit line backed by InvestEU to support clinical developments against long-COVID
Geneva, Switzerland, March 7, 2023 – 07:30 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), announced today the signature of a credit agreement for a total amount of up to EUR 25 million with the European Investment Bank (“EIB”), supported by the InvestEU programme.
GeNeuro announces recruitment of first patients in all five Swiss centers in the first personalized medicine clinical trial against long-COVID assessing temelimab
Geneva, Switzerland, November 16, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubünden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuro’s web site).
https://geneuro.ch/data/news/GeNeuro-Long-COVID-First-Patients-PR-November-16-2022.pdf
GeNeuro’s ProTEct-MS Phase 2 trial data, presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of temelimab in MS
Geneva, Switzerland, October 28, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the primary analysis of the Phase 2 ProTEct-MS study was presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022) Congress in Amsterdam, Netherlands, by Dr. Fredrik Piehl, Professor of Neurology at the Department of Clinical Neurosciences of the Karolinska Institutet, head of research at the MS clinic of the Academic Specialist Center (ASC), and Principal Investigator of the study.
https://geneuro.ch/data/news/GeNeuro-ECTRIMS-PR-Oct.-28-2022.pdf
The Karolinska Institutet’s Academic Specialist Center (ASC) to Present Results of GeNeuro’s ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022
Geneva, Switzerland, October 25, 2022, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced it will present Phase IIb safety and efficacy data on temelimab from its ProTEct-MS study at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, Netherlands.
https://geneuro.ch/data/news/GeNeuro-PR-ECTRIMS-2022-curtain-raiser-ENG-Oct.-25-2022.pdf
GeNeuro: financial information for the third quarter 2022
Geneva, Switzerland, October 24, 2022, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported on its 2022 third quarter cash position and issued a business update.
https://geneuro.ch/data/news/GeNeuro-PR-Q3-2022-EN-Oct.-24-2022.pdf
Presentation at the International Society of NeuroVirology 2022 of top-line data of academic collaborations further documenting the long-term expression of the Proinflammatory and Neuropathogenic W-ENV protein in cohorts of post-COVID Patients
Geneva, Switzerland, October 17, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled new data further documenting the presence of W-ENV in cohorts of post-COVID patients at the18th Symposium of the International Society of Neuro Virology (ISNV) held on October 11-14, 2022.
https://geneuro.com/data/news/GeNeuro-ISNV-presentation-ENG-Oct.-17-2022.pdf
Two studies on ALS published in Annals of Neurology demonstrate the neurotoxic role of human endogenous retrovirus envelope protein (HERV-K/HML-2 ENV) and the rationale for targeted therapy with specific antibody
Geneva, Switzerland, August 30, 2022 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (post-COVID), announced today the joint publications in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. The two publications describe the novel pathogenic mechanism of HERV-K in sporadic ALS and confirm the rationale for the therapeutic relevance of GeNeuro’s antibody to neutralize this neurotoxic protein.
https://geneuro.ch/data/news/2022-08-30-GeNeuro-PR-2-publications-ALS-Annals-of-Neurology.pdf
GeNeuro: financial information and business update for the second quarter 2022
Geneva, Switzerland, July 21, 2022, 5.45 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.
Study confirming the key role of human endogenous retroviruses (HERV-K) for ALS published in “Annals of Neurology”
Geneva, Switzerland, July 20, 2022 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today the publication in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. This publication describes the novel pathogenic mechanism of HERV-K in sporadic ALS and confirms the action of GeNeuro’s antibody to neutralize this toxicity.
https://geneuro.com/data/news/GeNeuro-PR-publication-SLA-EN-vf.pdf
GeNeuro Announces Approval of all Resolutions Proposed at 2022 Annual General Meeting
Geneva, Switzerland, June 2, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 31, 2022.
GeNeuro announces successful €7.7 million private placement
Geneva, Switzerland, May 12, 2022 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today announced the successful completion of a €7.7 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 2,678,251 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).
https://geneuro.ch/data/news/PR-GeNeuro-Closes-Financing-ENG-VF-May-12-2022.pdf
GeNeuro is granted authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post COVID syndromes
Geneva, Switzerland, May 11, 2022– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announces today it has received the authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post-COVID syndromes.
https://geneuro.ch/data/news/GeNeuro-PR-05112022-Swissmedic-approval-ENG-VF2.pdf